Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus

BACKGROUND: Although cardiovascular outcome trials using sodium-glucose cotransporter-2 inhibitors (SGLT-2i) showed a reduction in risk of 3-point major adverse cardiovascular events (MACE), they did not demonstrate beneficial effects on stroke risk. Additionally, meta-analysis showed SGLT-2i potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Seung Eun, Nam, Hyewon, Choi, Han Seok, Kim, Hoseob, Kyoung, Dae-Sung, Kim, Kyoung-Ah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353567/
https://www.ncbi.nlm.nih.gov/pubmed/35130688
http://dx.doi.org/10.4093/dmj.2021.0160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353567/
https://www.ncbi.nlm.nih.gov/pubmed/35130688
http://dx.doi.org/10.4093/dmj.2021.0160

Ejemplares similares